2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Nanosomal formulation of a vitamin D receptor alkylating compound for prostate cancer

R. Ray and T. Castor
Boston University School of Medicine, US

Keywords:
vitamin D derivative, nanosomal formulation, receptor-targeted drug, prostate cancer

Abstract:
An inverse relationship between incidence and mortality from various cancers and dietary vitamin D is well-established. Furthermore, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the vitamin D hormone has strong antiproliferative effects in cancer cells. But it is highly toxic in therapeutic doses. In vitro tests of 1,25-dihydroxyvitamin D3-3-bromoacetate (1,25(OH)2D3-3-BE), a derivative of 1,25(OH)2D3 designed and selectively targeted to have increased antiproliferative effect while reducing systemic toxicity through alkylation of the ligand-binding domain of vitamin D receptor in tumor cells, have demonstrated that this compound has strong growth-inhibitory and apoptosis-inducing properties in hormone-sensitive and hormone-insensitive prostate cancer cells, significantly stronger than 1,25(OH)2D3. Furthermore, preliminary in vivo studies showed that 1,25(OH)2D3-3-BE is of low-toxicity, and it strongly reduces androgen-refractory prostate tumor in a mouse xenograft model. Phospholipid nanosomes are small, uniform liposomes that are made up of biocompatible phospholipids and cholesterol; and they are designed to encapsulate vitamin D drugs in the lipid-bilayer of the nansomes. Nanosomal formulation of 1,25(OH)2D3-3-BE is designed to further reduce systemic toxicity, increase circulatory half-life and efficacy resulting in an improved therapeutic index for this vitamin D–based drug in prostate cancer.

Back to Program

Sessions Sunday Monday Tuesday Wednesday Thursday Authors Keywords

Nanotech 2007 Conference Program Abstract

 
 

Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.